Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Saad, Fred, Clarke, Noel W, Oya, Mototsugu · The Lancet Oncology · 2023